Emerging Functions of RANKL in Lymphoid Tissues
- PMID: 22969763
- PMCID: PMC3432452
- DOI: 10.3389/fimmu.2012.00261
Emerging Functions of RANKL in Lymphoid Tissues
Abstract
The tumor necrosis factor superfamily (TNFSF) members play pivotal roles in embryonic development of lymphoid tissue and their homeostasis. RANKL (Receptor activator of NF-κB ligand, also called TRANCE, TNFSF11) is recognized as an important player in bone homeostasis and lymphoid tissue formation. In its absence bone mass control is deregulated and lymph nodes fail to develop. While its function in bone is well described, there is still little functional insight into the action of RANKL in lymphoid tissue development and homeostasis. Here we provide an overview of the known functions of RANKL, its signaling receptor RANK and its decoy receptor OPG from the perspective of lymphoid tissue development and immune activation in the mouse. Expressed by the hematopoietic lymphoid tissue inducing (LTi) cells and the mesenchymal lymphoid tissue organizer (LTo) cells, RANKL was shown to stimulate Lymphotoxin (LT) expression and to be implicated in LTi cell accumulation. Our recent finding that RANKL also triggers proliferation of adult lymph node stroma suggests that RANKL may furthermore directly activate LTo cells. Beyond bone, the RANKL-RANK-OPG triad plays important roles in immunobiology that are waiting to be unraveled.
Keywords: LTi; LTo; OPG; TNFSF11; TRANCE; lymph node; lymphoid organs; stroma.
Figures






Similar articles
-
Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond.Front Immunol. 2014 Oct 20;5:511. doi: 10.3389/fimmu.2014.00511. eCollection 2014. Front Immunol. 2014. PMID: 25368616 Free PMC article. Review.
-
Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.J Bone Miner Res. 2001 Aug;16(8):1416-25. doi: 10.1359/jbmr.2001.16.8.1416. J Bone Miner Res. 2001. PMID: 11499864
-
OPG, RANK and RANK ligand expression in thyroid lesions.Regul Pept. 2008 Jun 5;148(1-3):46-53. doi: 10.1016/j.regpep.2008.02.004. Epub 2008 Feb 19. Regul Pept. 2008. PMID: 18367263
-
Expression pattern changes and function of RANKL during mouse lymph node microarchitecture development.Int Immunol. 2012 Jun;24(6):369-78. doi: 10.1093/intimm/dxs002. Epub 2012 Feb 21. Int Immunol. 2012. PMID: 22354913
-
Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).Mol Med Rep. 2015 May;11(5):3212-8. doi: 10.3892/mmr.2015.3152. Epub 2015 Jan 7. Mol Med Rep. 2015. PMID: 25572286 Review.
Cited by
-
Immune function and dysfunction are determined by lymphoid tissue efficacy.Dis Model Mech. 2022 Jan 1;15(1):dmm049256. doi: 10.1242/dmm.049256. Epub 2022 Jan 24. Dis Model Mech. 2022. PMID: 35072206 Free PMC article. Review.
-
Loss of vascular endothelial notch signaling promotes spontaneous formation of tertiary lymphoid structures.Nat Commun. 2022 Apr 19;13(1):2022. doi: 10.1038/s41467-022-29701-x. Nat Commun. 2022. PMID: 35440634 Free PMC article.
-
Maternal RANKL Reduces the Osteopetrotic Phenotype of Null Mutant Mouse Pups.J Clin Med. 2018 Nov 8;7(11):426. doi: 10.3390/jcm7110426. J Clin Med. 2018. PMID: 30413057 Free PMC article.
-
Targeting the RANKL/RANK/OPG Axis for Cancer Therapy.Front Oncol. 2020 Aug 7;10:1283. doi: 10.3389/fonc.2020.01283. eCollection 2020. Front Oncol. 2020. PMID: 32850393 Free PMC article. Review.
-
Tumor necrosis factor receptor- associated factor 6 (TRAF6) regulation of development, function, and homeostasis of the immune system.Immunol Rev. 2015 Jul;266(1):72-92. doi: 10.1111/imr.12302. Immunol Rev. 2015. PMID: 26085208 Free PMC article. Review.
References
-
- Akiyama T., Shimo Y., Yanai H., Qin J., Ohshima D., Maruyama Y., Asaumi Y., Kitazawa J., Takayanagi H., Penninger J. M., Matsumoto M., Nitta T., Takahama Y., Inoue J. (2008). The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity 29, 423–43710.1016/j.immuni.2008.06.015 - DOI - PubMed
-
- Alimzhanov M. B., Kuprash D. V., Kosco-Vilbois M. H., Luz A., Turetskaya R. L., Tarakhovsky A., Rajewsky K., Nedospasov S. A., Pfeffer K. (1997). Abnormal development of secondary lymphoid tissues in lymphotoxin beta-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 94, 9302–930710.1073/pnas.94.17.9302 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources